TIDMETX

RNS Number : 6936X

e-Therapeutics plc

07 January 2022

E-THERAPEUTICS PLC

("e-therapeutics" or the "Company")

DIRECTOR DEALING AND ISSUE OF EQUITY

Oxford, UK, 7 January 2022 - e-therapeutics plc (AIM: ETX), the drug discovery company, announces that o n 6 January 2022, Professor Trevor Jones (Non-Executive Chairman of the Company) subscribed for a total of 17,471 new ordinary shares of 0.1p each in the Company (the "New Ordinary Shares") a t a price of 43.28 pence per

share. The subscription monies paid for the New Ordinary Shares represent   50% of Professor Jones' Non-Executive Director fees net of tax paid during the period from 1 July 2021 to 31 December 2021 in accordance with the agreement entered into with Professor Jones, previously announced o n 5 October 2016, by which Professor Jones agreed, with effect from 1 October 2016, to invest 50% of his annual Non-Executive Director fees net of tax in new e-therapeutics' ordinary shares. Such new shares are issued to Professor Jones on the first business day after 31 December and 30 June in each year. The subscription price to be paid is the average of the closing mid-market price for the five business days prior to the date of issue.

Following Admission, Professor Jones will be interested in a total of 1,079,478 ordinary shares of 0.1p in the Company, representing approximately 0.21% of the Company's issued share capital.

Application has been made to AIM for the admission of the New Ordinary Shares to trading on AIM ("Admission") and Admission is expected to occur at 8:00 a.m. on or around 13 January 2022. The New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares in issue.

Following Admission, the total number of ordinary shares in the Company with voting rights in issue will be 514,571,069. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:

 
 1    Details of the person discharging managerial responsibilities/person 
       closely associated 
 a)   Name                        Trevor Jones 
     --------------------------  ------------------------------------------- 
 2    Reason for the notification 
     ----------------------------------------------------------------------- 
 a)   Position/status             Non-Executive Chairman 
     --------------------------  ------------------------------------------- 
 b)   Initial notification/       Initial notification 
       Amendment 
     --------------------------  ------------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ----------------------------------------------------------------------- 
 a)   Name                        e-therapeutics plc 
     --------------------------  ------------------------------------------- 
 b)   LEI                         21380049RHSSJXWKYT18 
     --------------------------  ------------------------------------------- 
 4    Details of the transaction(s): section to be repeated for (i) 
       each type of instrument; (ii) each type of transaction; (iii) 
       each date; and (iv) each place where transactions have been 
       conducted 
     ----------------------------------------------------------------------- 
 a)   Description of the          Ordinary Shares of 0.1 pence 
       financial instrument, 
       type of instrument          ISIN: GB00B2823H99 
       Identification code 
     --------------------------  ------------------------------------------- 
 b)   Nature of the transaction   Purchase of shares 
     --------------------------  ------------------------------------------- 
 c)   Price(s) and volume(s)      17,471 ordinary shares at a price of 43.28 
                                   pence per share 
     --------------------------  ------------------------------------------- 
 d)   Aggregated information      17,471 ordinary shares 
       - Aggregated volume         43.28 pence per share 
       - Price                     Aggregated value: GBP7,561.45 
     --------------------------  ------------------------------------------- 
 e)   Date of the transaction     6 January 2022 
     --------------------------  ------------------------------------------- 
 f)   Place of the transaction    Outside a trading venue 
     --------------------------  -------------------------------------------

For further information, please contact:

 
 e-therapeutics plc 
 Ali Mortazavi, CEO                                 Tel: +44 (0)1993 
  Laura Roca-Alonso, CBO                                     883 125 
                                             www.etherapeutics.co.uk 
 
 SP Angel Corporate Finance LLP 
 Nominated Adviser and Broker                     Tel: +44(0)20 3470 
                                                                0470 
 Matthew Johnson/Caroline Rowe (Corporate 
  Finance) 
 Vadim Alexandre/Rob Rees (Corporate 
  Broking)

About e-therapeutics plc

e-therapeutics plc is an Oxford, UK-based company integrating computational power and biology to accelerate the discovery of life-transforming medicines. The Company has developed and validated a powerful, disease and modality agnostic computational approach to drug discovery, leveraging its industry-leading expertise in network biology to fully capture and interrogate human disease complexity.

The Company's multi-disciplinary team builds computational models of biological functions to transform the search for new medicines, interventions, mechanisms and genetic support. Its biology-led in silico laboratory enables rapid hypothesis generation and phenotypic screening of millions of compounds leading to 100-1000x higher hit rates in the wet lab and successful mode of action elucidation. Novel targets can also be identified, prioritised and assessed. Harnessing internal target gene discoveries, e-therapeutics is currently building an in-house pipeline of RNAi based medicines, using its proprietary GalNAc-siRNA technology.

e-therapeutics has deployed and validated its disease-agnostic computational drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEFLFLRLRIRIIF

(END) Dow Jones Newswires

January 07, 2022 01:59 ET (06:59 GMT)

E-therapeutics (LSE:ETX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas E-therapeutics.
E-therapeutics (LSE:ETX)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas E-therapeutics.